Centre for Pulmonary Hypertension at Thoraxclinic Heidelberg, Thoraxclinic at the University Hospital Heidelberg, Amalienstrasse 5, Heidelberg, 69126, Germany.
Arthritis Res Ther. 2012 Jun 18;14(3):R148. doi: 10.1186/ar3883.
The objective of this prospective study was to assess short- and long-term efficacy of exercise training (ET) as add-on to medical therapy in patients with connective tissue disease-associated pulmonary arterial hypertension (CTD-APAH).
Patients with invasively confirmed CTD-APAH received ET in-hospital for 3 weeks and continued at home for 12 weeks. Efficacy parameters have been evaluated at baseline and after 15 weeks by blinded-observers. Survival rate has been evaluated in a follow-up period of 2.9 ± 1.9 years.
Twenty-one consecutive patients were included and assessed at baseline, and after 3 weeks, 14 after 15 weeks. Patients significantly improved the mean distance walked in 6 minutes compared to baseline by 67 ± 52 meters after 3 weeks (p < 0.001) and by 71 ± 35 meters after 15 weeks (p = 0.003), scores of quality of life (p < 0.05), heart rate at rest, peak oxygen consumption, oxygen saturation and maximal workload. Systolic pulmonary artery pressure and diastolic systemic blood pressure improved significantly after 3 weeks of ET. The 1- and 2-year overall-survival rates were 100%, the 3-year survival 73%. In one patient lung transplantation was performed 6 months after ET.
ET as add-on to medical therapy is highly effective in patients with CTD-APAH to improve work capacity, quality of life and further prognostic relevant parameters and possibly improves the 1-, 2- and 3-year survival rate. Further randomized controlled studies are needed to confirm these results.
ClinicalTrials.gov: NCT00491309.
本前瞻性研究旨在评估运动训练(ET)作为结缔组织病相关肺动脉高压(CTD-APAH)患者药物治疗的附加手段的短期和长期疗效。
接受有创性确诊的 CTD-APAH 患者在医院接受 3 周的 ET,然后在家中继续接受 12 周的 ET。疗效参数由盲法观察者在基线和 15 周时进行评估。在 2.9±1.9 年的随访期间评估生存率。
连续纳入 21 例患者,在基线时、3 周后和 15 周后进行评估。与基线相比,患者在 3 周后 6 分钟内行走的平均距离增加了 67±52 米(p<0.001),在 15 周后增加了 71±35 米(p=0.003),生活质量评分(p<0.05)、静息心率、峰值摄氧量、氧饱和度和最大工作量也有所改善。ET 治疗 3 周后,收缩期肺动脉压和舒张期全身血压显著改善。1 年和 2 年的总生存率为 100%,3 年生存率为 73%。1 例患者在 ET 后 6 个月进行了肺移植。
ET 作为药物治疗的附加手段,可有效改善 CTD-APAH 患者的工作能力、生活质量和进一步预后相关参数,并可能提高 1 年、2 年和 3 年的生存率。需要进一步的随机对照研究来证实这些结果。
ClinicalTrials.gov:NCT00491309。